Key result
Etanercept decreased the cost of an annual therapy cycle for rheumatoid arthritis by an average of 84,764–481,622 rubles compared to alternative biological agents.
Why the study?
Is etanercept more cost-effective than other biological agents in patients with rheumatoid arthritis?
Is etanercept more cost-effective than other biological agents in patients with rheumatoid arthritis?
Etanercept is a cost-effective biological agent for rheumatoid arthritis that can reduce annual therapy costs and allow more patients to be treated within the same budget.
No takes yet. Share an insight, caveat, or question.
Etanercept lowers annual RA therapy costs versus alternatives; supports preferential use to expand access within fixed budgets.
Dyakov et al. (2014) studied Rheumatoid arthritis. Etanercept (ETC) vs. Alternative biological agents was evaluated on Cost of an annual therapy cycle. Etanercept decreased the cost of an annual therapy cycle for rheumatoid arthritis by an average of 84,764–481,622 rubles compared to alternative biological agents.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: